Alterations in lipidic metabolism in hemodialysis patients

##plugins.themes.academic_pro.article.sidebar##

Published Jul 6, 2012
Download
pdf
Vol. 90 No. 7 (2012): Issue Jul 2012

##plugins.themes.academic_pro.article.main##

Inés Kharrat
Aouatef Jmal
Lobna Jmal
Zeineb Amira
Walid Ben Cheikh
Férid Ben Bourouba
Lotfi Sahnoun
Monia Abdennebi

Abstract

Background: Chronic kidney failure is associated with dyslipidemia and accelerated atherosclerosis.
Aim: To study lipidic metabolism alterations in patients with chronic kidney failure on hemodialysis.
Methods: The study interested 45 hemodialysis patients with a mean age of 49.04 ±15.92 years old and 45 healthy controls. A blood sample was collected from each patient and control to measure total cholesterol, triglycerides, HDL- cholesterol, LDL-cholesterol, apolipoproteins AI and B100, lipoprotein (a) and C Reactive Protein.
Results: A significant increase of serum triglycerides (p= 0.002), lipoprotein (a) (p = 0.001) and C Reactive Protein (p = 0.008) was observed in patients when compared with healthy controls. A significant decrease of serum total cholesterol (p=0.01), HDLcholesterol (p<0.001), LDL-cholesterol (p=0.005) and apolipoprotein AI (p<0.001) was also observed in patients.
Conclusion: Disorders of lipidic metabolism are frequent in hemodialysis patients. These alterations can lead to cardiovascular disease in uremic patients.

Keywords:

Chronic kidney failure, hemodialysis, cardiovascular disease, metabolic alterations

##plugins.themes.academic_pro.article.details##

References

  1. Kessler M. Insuffisance rénale chronique. Etiologie, physiopathologie, diagnostic, principes du traitement. Rev Prat 1998; 48:1457-63.
  2. Guebre-Egziabher F, Fouque D. Altérations métaboliques au cours de l'insuffisance rénale chronique. Nutr Clin Métab 2004 ; 18 : 3-6.
  3. Cibulka R, Racek J. Metabolic disorders in patients with chronic kidney failure. Physiol Res 2007; 56: 697-705.
  4. AFSSPS 2005. Prise en charge du patient dyslipidémique.
  5. Sabouret P. Prise en charge des dyslipidémies des patients coronariens. Sang Thrombose Vaisseaux 2006 ; 18 : 125-34.
  6. Fouton T, Laporte F, Payen N, Groslambert P. Apolipoprotéine AI et B plasmatiques : valeurs usuelles de la population de l'Isère et détermination de valeurs seuil. Ann Biol Clin 1998 ; 56 : 451-56.
  7. Schaefer Ej, Lamon-Fava S, Cohn SD et al. Effects of age, gender, and meopausal status on plasma low density lipoprotein cholesterol and apolipoprotein B levels in the Framingham Offspring Study. J Lipid Res 1994 ; 35: 779-92.
  8. Thisseni JP. Normes du cholestérol. Louvain Med 1999 ; 118 : 139-144.
  9. Chauhan V, Vaid M. Dyslipidemia in chronic kidney disease: managing a high-risk combination. Postgrad Med 2009; 121:54-61.
  10. Shoji T, Nishizawa Y. Plasma lipoprotein abnormalities in hemodialysis patients : Clinical implications and therapeutic guidelines. Ther Apher Dial 2006; 10 :305-15.
  11. Madore F. Facteurs de risque cardiovasculaire et insuffisance rénale. Medecine/science 2004; 20: 1100-3.
  12. Prinsen Bh, De Sain-Van Der Velden Mg, De Koning Ej, Koomans Ha, Berger R, Rabelink TJ. Hypertriglyceridemia in patients with chronic renal failure: possible mechanisms. Kidney Int Suppl 2003; 84:S121-4.
  13. Lacour B, Massy Z, Jungers P, Dureke T. Anomalies du métabolisme des lipoprotéines dans l'insuffisance rénale chronique. Néphrologie 1993 ; 14 : 75-90.
  14. Jamoussi K, Ayedi F, Abida N et al. Profil lipidique dans l'insuffisance rénale chronique au stade d'hémodialyse. Pathol Biol (Paris) 2005; 53: 217-20.
  15. Piperi C, Kalofoutis C, Tzivras M, Troupis T, Skenderis A, Kalofoutis A. Effects of hemodialysis on serum lipids and phospholipids of end-stage renal failure patients. Mol Cell Biochem 2004; 265:57-61.
  16. Lippi G, Tessitore N, Gammaro L, Rugiu C, Mashio G, Guidi G. Cardiovascular risk factors in patients with chronic renal failure on hemodialysis or continuous ambulatory peritoneal dialysis. Thromb Res 2001; 101:517-19.
  17. Maheshwari N, Ansari Mr, Laghari Ms, Darshana, Lal K, Ahmed K. Pattern of lipid profile in patients on maintenance hemodialysis. Saudi J Kidney Dis Transplant 2010; 21:565-70.
  18. Moulin B. Anomalies lipidiques au cours de l'insuffisance rénale: conséquences sur la progression de l'insuffisance rénale et le risque cardiovasculaire. Néphrologie 2000; 21: 339-41.
  19. Vaziri ND. Dyslipidemia of chronic renal failure: the nature, mechanisms, and potential consequences. Am J Physiol Renal Physiol 2006; 290: 262-72.
  20. Helal I, Smaoui W, Ben Hamida F et al. Cardiovascular risk factors in hemodialysis and peritoneal dialysis patients. Saudi J Kidney Dis Transpl 2010; 21: 59-62.
  21. Charriere S, Rognant N, Chiche F, Cremer A, Deray G, Priou M. Insuffisance rénale chronique et maladie cardiovasculaire. Ann Cardiol Angeiol 2009 ; 58: 40-52.
  22. Kalantar-Zadeh K, Ikizler Ta, Block G, Avram Mm, Kopple JD. Malnutrition-inflammation complex syndrome in dialysis patients : causes and consequences. Am J Kidney Dis 2003; 42: 864-81.
  23. Kalantar-Zadeh K, Stenvinkel P, Pillon L, Kopple JD. Inflammation and nutrition in renal insufficiency. Adv Ren Replace Ther 2003; 10:155-69.
  24. Fytili Ci, Progia Eg, Panagoutsos SA et al. Lipoprotein abnormalities in hemodialysis and continuous ambulatory peritoneal dialysis patients. Ren Fail 2002; 24:623-30.
  25. Lee Dm, Knight-Gibson C, Samuelsson O, Attman Po, Wang Cs,Alaupovic P. Lipoprotein particle abnormalities and the impaired lipolysis in renal insufficiency. Kidney Int 2002; 61:209-18.
  26. Nasri H, Baradaran A. Association of early atherosclerotic vascular changes with serum lipoprotein (a) in predialysis chronic renal failure and maintenance hemodialysis patients. Saudi J Kidney Dis Transplant 2005; 16:154-60.
  27. Frischmann Me, Kronenberg F, Trenkwalder E et al. In vivo turnover study demonstates diminished clearance of lipoprotein (a) in hemodialysis patients. Kidney int 2007; 71:1036-43.
  28. Reblin T, Donarski N, Fineder L et al. Renal handling of human apolipoprotein (a) and its fragments in the rat. Am J Kidney Dis 2001; 38: 619-30.
  29. Kostner Km, Clodi M, Bodlaj G et al. Decreased urinary apolipoprotein (a) excretion in patients with impaired renal function. Eur J Clin Invest 1998; 28: 447-52.
  30. Stenvinkel P, Heimburger O, Petterson E, Berglund L, Alvestrand A. Lipoprotein(a) in renal disease. J Am Soc Nephrol 1993;4:258.
  31. Stenvinkel P, Heimburger O, Tuck Ch, Berglund L. Apo (a) isoform size, nutritional status and inflammatory markers in chronic renal failure. Kidney Int 1998; 53:1336-42.
  32. Kronenberg F, Utermann G, Dieplinger H. Lipoprotein (a) in renal disease. Am J Kidney Dis 1996; 27:1-25.
  33. Noma A, Abe A, Maeda S et al. Lp (a): an acute phase reactant? Chem Phys Lipids 1994; 67-68: 411-7.
  34. Topciu Shufta V, Begolli L, Kryeziu E. Lipoprotein (a) as an acute phase reactant in patients on chronic hemodialysis. Bosn J Basic Med Sci 2010; 10:19-25.
  35. Szumilak D, Khoa Tn, Touam M, Jungers P, Lacour B, Maszsy ZA. Lipides et risque cardiovasculaire au cours de l'insuffisance rénale chronique. Nutr Clin Metab 1999; 13: 187-90.
  36. Bevc S, Hojs R, Ekart R, Hojs-Fabjan T. Atherosclerosis in hemodialysis patients: traditional and nontraditional risk factors. Acta Dermatovenerol Alp Panonica Adriat 2006; 15: 151-7.